Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs

Association of Complement Factor H and ARMS2 Genotypes With Response of Polypoidal Choroidal Vasculopathy to Intravitreal Ranibizumab

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01271426

Enrollment

Registered

2011-01-06

Start date

2008-04-30

Completion date

2010-03-31

Last updated

2011-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polypoidal Choroidal Vasculopathy

Keywords

Polypoidal Choroidal Vasculopathy, Ranibizumab

Brief summary

To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of Polypoidal choroidal vasculopathy * must have injection of Ranibizumab

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
Association of Complement Factor H and ARMS2 Genotypes with Response of Polypoidal Choroidal Vasuculopathy to Intravitral Ranibizumab	a month after injection

Countries

Japan

Outcome results